What is HC Wainwright’s Estimate for PTGX FY2024 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Protagonist Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst D. Tsao now expects that the company will earn $1.82 per share for the year, up from their previous forecast of $1.44. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.53) EPS, FY2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.55) EPS and FY2027 earnings at ($0.41) EPS.

Several other equities analysts have also recently issued reports on PTGX. BTIG Research lifted their price objective on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. JMP Securities cut their price objective on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 7th. Truist Financial began coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $53.57.

Protagonist Therapeutics Trading Up 0.2 %

Shares of Protagonist Therapeutics stock opened at $41.11 on Thursday. Protagonist Therapeutics has a 52 week low of $15.58 and a 52 week high of $48.89. The stock has a market cap of $2.45 billion, a PE ratio of 15.45 and a beta of 2.17. The company’s 50-day moving average price is $45.64 and its two-hundred day moving average price is $38.50.

Insider Activity

In related news, Director William D. Waddill sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. The trade was a 40.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Asif Ali sold 14,203 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the sale, the chief financial officer now owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. The trade was a 28.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PTGX. Farallon Capital Management LLC boosted its position in Protagonist Therapeutics by 1.8% during the second quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock valued at $202,383,000 after purchasing an additional 101,800 shares during the last quarter. RTW Investments LP raised its stake in shares of Protagonist Therapeutics by 2.6% during the 3rd quarter. RTW Investments LP now owns 5,426,112 shares of the company’s stock worth $244,175,000 after purchasing an additional 139,708 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Protagonist Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after buying an additional 39,055 shares during the last quarter. State Street Corp grew its stake in shares of Protagonist Therapeutics by 52.9% in the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company’s stock valued at $143,259,000 after buying an additional 1,101,218 shares in the last quarter. Finally, Pacer Advisors Inc. raised its position in Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock valued at $78,034,000 after acquiring an additional 1,733,662 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.